Flumazenil B. Braun, 0.1 mg/ml, solution for injection
Flumazenil B. Braun is an antidote for a specific group of medicines called benzodiazepines. Benzodiazepines have a calming, sleep-inducing, and muscle-relaxing effect. They are used for sedation and calming in case of anxiety. Flumazenil B. Braun can completely or partially reverse these effects.
Flumazenil B. Braun can also be used for diagnosis and treatment of benzodiazepine poisoning or overdose. Flumazenil B. Braun is used in children over 1 year of age to wake them up after benzodiazepines have been used to sedate them for a medical procedure.
Special caution is needed
After administration of Flumazenil B. Braun, the patient's consciousness and vital functions (i.e., blood pressure, heart rate, breathing rate) will be monitored for a suitable period. Since the effect of Flumazenil B. Braun is usually shorter than that of benzodiazepines, a return of sedation is possible. The patient will be closely monitored, possibly in an intensive care unit, until the effect of Flumazenil B. Braun has worn off.
Children who have been given midazolam should be under close observation in an intensive care unit for at least 2 hours after administration of Flumazenil B. Braun. Sedation or respiratory difficulties may recur. In cases of sedation caused by other benzodiazepines, the observation phase for the patient should be adjusted according to the expected duration of action of the medicine. Flumazenil B. Braun can be given to children under 1 year of age only if the potential benefit outweighs the risk (see also section 2 "Warnings and precautions, Children").
Tell your doctor about all the medicines you have taken recently, even those that are available without a prescription. Flumazenil B. Braun reverses the effects of all medicines that act on the benzodiazepine receptor. This includes medicines that are not benzodiazepines but have the same mechanism of action, such as zopiclone (e.g., zimovane), triazolopyridazine, and others. Benzodiazepines may mask the toxic effects of certain psychotropic medicines (especially tricyclic antidepressants, e.g., imipramine, see also section 2 "Warnings and precautions"). When using Flumazenil B. Braun in case of overdose, it should be taken into account that the toxic effects of such medicines taken at the same time may increase as the effect of benzodiazepines wears off.
If you are pregnant or breastfeeding, or think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Due to the lack of sufficient experience, Flumazenil B. Braun should be used during pregnancy with caution and only when the benefit to the patient outweighs the potential risk to the unborn child. There are no contraindications to the use of Flumazenil B. Braun during pregnancy in emergency situations. It is not known whether Flumazenil B. Braun passes into breast milk. Therefore, breastfeeding should be discontinued for 24 hours after administration of Flumazenil B. Braun. There are no contraindications to the use of Flumazenil B. Braun during breastfeeding in emergency situations.
After receiving Flumazenil B. Braun to reverse the effects of benzodiazepines, you should not drive vehicles, operate machinery, or engage in other activities that require physical or mental activity for at least 24 hours, as the sedative effect of benzodiazepines may return.
The medicine contains less than 1 mmol (23 mg) of sodium per ml of solution for injection, which means that the medicine is essentially sodium-free.
Flumazenil B. Braun is administered by an anesthesiologist or an experienced doctor. Flumazenil B. Braun is given as an intravenous injection (into a vein) or as a diluted solution as an intravenous infusion (slow injection into a vein). Flumazenil B. Braun can be used at the same time as other agents to restore basic life functions. The recommended dose is:
Adults | |
Anesthesia | Intensive care |
Dosing method: | |
Initial dose: 0.2 mg administered intravenously over 15 seconds. | Initial dose: 0.3 mg administered intravenously. |
A further dose of 0.1 mg can be injected and repeated at 60-second intervals; if an adequate level of consciousness is not achieved within 60 seconds, a maximum of 1.0 mg can be administered. | A further dose of 0.1 mg can be injected and repeated at 60-second intervals; if an adequate level of consciousness is not achieved within 60 seconds, a maximum of 2.0 mg can be administered. |
Usual dose is from 0.3 mg to 0.6 mg, but may vary depending on individual patient characteristics and benzodiazepines taken. | In case of recurrence of sedation, a second injection of the dose may be effective. An intravenous infusion of 0.1-0.4 mg/h may be beneficial. The infusion rate should be adjusted individually to achieve the desired level of consciousness. |
The infusion should be interrupted every 6 hours to check if sedation returns.
Intravenous injection of 0.01 mg/kg body weight (up to 0.2 mg) administered over 15 seconds. If an adequate level of consciousness is not achieved after 45 seconds, a further dose of 0.01 mg/kg body weight (up to 0.2 mg) can be administered. If necessary, injections can be repeated at 60-second intervals (up to 4 times), up to a maximum dose of 0.05 mg/kg body weight or 1 mg, whichever is lower.
There is insufficient data on the use of Flumazenil B. Braun in children under 1 year of age. Therefore, Flumazenil B. Braun can be administered to children under 1 year of age only if the potential benefit outweighs the risk (see also section 2 "Warnings and precautions, Children").
In patients with impaired liver function, the elimination of Flumazenil B. Braun may be delayed, and therefore, careful dose adjustment is recommended. There is no need to adjust the dose in patients with impaired renal function. In case of doubt, consult your doctor or pharmacist. Information intended for healthcare professionals can be found in one of the sections below.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common(may affect more than 1 in 10 people):
Uncommon(may affect more than 1 in 100 people):
Rare(cannot be estimated from the available data):
Common(may affect more than 1 in 10 people):
Uncommon(may affect more than 1 in 100 people):
Rare(cannot be estimated from the available data):
In cases of long-term treatment with benzodiazepines, Flumazenil B. Braun may cause withdrawal symptoms (frequency not known). Symptoms include: agitation, anxiety, emotional instability, disorientation, and sensory disturbances. In general, side effects in children are similar to those in adults. When using Flumazenil B. Braun to wake up a child, excessive crying, agitation, and aggressive reactions may occur.
If you experience any side effects, including those not listed in the leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, ul. Ząbkowska 41, 03-736 Warsaw, Tel. (22) 4921 301, Fax. (22) 4921 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children. Do not use Flumazenil B. Braun after the expiry date stated on the label and carton after EXP. The expiry date refers to the last day of that month. Do not store above 25°C. The medicinal product is for single use only. Shelf life after first opening: the medicinal product should be used immediately. Shelf life after dilution: 24 hours. Chemical and physical stability, ensuring the quality of the product, was maintained for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the responsibility for the storage time and conditions that ensure the quality of the product lies with the user and should not exceed 24 hours at 2°C to 8°C, unless the concentrate has been diluted in controlled and approved aseptic conditions. Before use, the solution should be inspected visually. Do not use Flumazenil B. Braun if the solution is not clear, colorless, and free of precipitates. Unused solution should be disposed of in accordance with local requirements. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance is flumazenil. Each milliliter contains 0.1 mg of flumazenil. Each 5 ml ampoule contains 0.5 mg of flumazenil. Each 10 ml ampoule contains 1.0 mg of flumazenil. The other ingredients are acetic acid, sodium chloride, disodium edetate, sodium hydroxide, 1N solution, water for injections.
Flumazenil B. Braun is a clear and colorless solution for injection and concentrate for infusion in ampoules made of colorless glass. The following packs are available: cardboard boxes of 5 or 10 ampoules containing 5 ml of solution. Cardboard boxes of 5 or 10 ampoules containing 10 ml of solution. Not all pack sizes may be marketed.
Tel. +49 5661/71-0 Fax +49 5661/71-4567 This medicinal product has been authorized in the Member States of the European Economic Area under the following names: Austria Flumazenil B. Braun 0.1 mg/ml Injektionslösung und Konzentrat zur Herstellung einer Infusionslösung Belgium Flumazenil B. Braun 0.1 mg/ml oplossing voor injectie Germany Flumazenil B. Braun 0.1 mg/ml Injektionslösung und Konzentrat zur Herstellung einer Infusionslösung Spain Flumazenil B. Braun 0.1 mg/ml solucion inyectable EFG Finland Flumazenil B.Braun 0.1 mg/ml injektioneste, liuos Iceland Flumazenil B. Braun 0.1 mg/ml stungulyf Italy Flumazenil B. Braun 0.1 mg/ml, soluzione iniettabile Luxembourg Flumazenil B. Braun 0.1 mg/ml Injektionslösung und Konzentrat zur Herstellung einer Infusionslösung Netherlands Flumazenil B. Braun 0.1 mg/ml oplossing voor injectie Poland Flumazenil B. Braun 0.1 mg/ml roztwór do wstrzykiwań Portugal Flumazenilo B. Braun 0.1 mg/ml solução injectável Sweden Flumazenil B.Braun 0.1 mg/ml injektionsvätska, lösning Date of last revision of the leaflet: 2023-05-02 -----------------------------------------------------------------------------------------------------------
If Flumazenil B. Braun is to be used as an infusion, it should be diluted first. Flumazenil B. Braun should be diluted only with sodium chloride 9 mg/ml (0.9% w/v), glucose 50 mg/ml (5% w/v), or sodium chloride 4.5 mg/ml (0.45% w/v) + glucose 25 mg/ml (2.5% w/v). The compatibility of Flumazenil B. Braun with other solutions for injection has not been established. The medicinal product should not be mixed with other medicinal products except those mentioned in this section.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.